MUMBAI, (GNI): Amit Bakshi, Chairman and Managing Director, Eris Lifesciences Ltd addressing at the press conference to announce the IPO of the company. The issue will open for subscription on Friday 16th and closes on Tuesday 20th June 2017 in Mumbai Photo by Sumant Gajinkar
MUMBAI, (GNI): Eris Lifesciences Limited (the “Company” or “Issuer”) proposes to open on Friday, June 16, 2017, an initial public offering of equity shares of face value of Re. 1 each (“Equity Shares”) for cash (the “Offer”) comprising of Offer For Sale of Equity Shares aggregating up to 28,875,000 Equity Shares by Selling Shareholders (“Offer For Sale”). The Bid/ Offer will close on Tuesday, June 20, 2017.
The Price Band for the Offer is fixed from Rs. 600 to Rs. 603 per Equity Share. Bids can be made for a minimum of 24 Equity Shares and in multiples of 24 Equity Shares thereafter, announced by Amit Bakshi, Chairman and Managing Director, Eris Lifesciences Ltd.
The Book Running Lead Managers (“BRLMs”) to the Offer are Axis Capital Limited, Citigroup Global Markets India Private Limited and Credit Suisse Securities (India) Private Limited.
The Company and Investor Selling Shareholder may, in consultation with the BRLMs, consider participation by Anchor Investors in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended (“SEBI ICDR Regulations”). The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Offer Opening Date; i.e., Thursday, June 15, 2017.
The Equity Shares offered through the RHP are proposed to be listed on BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”).
In terms of Rule 19(2)(b)(iii) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) and in accordance with Regulation 26(2) of the SEBI ICDR Regulations, the Offer is being made through the Book Building Process, wherein 75% of the Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”), provided that the Company and the Investor Selling Shareholder may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”) at the Anchor Investor Allocation Price, out of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not more than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential investors, other than Anchor Investors, are required to mandatorily use the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank accounts which will be blocked by the Self Certified Syndicate Banks (“SCSBs”) to participate in the Offer. For details, see “Offer Procedure” on Page 292 of the Red Herring Prospectus dated June 6, 2017 (“RHP”). For more information, visit Eris Lifesciences Limited at http://www.eris.co.in